HMX3 has been shown to integrate ESR1 and HER2 receptor tyrosine kinase signaling to promote aromatase expression and hormone resistance in a preclinical model of luminal breast cancer (Cortez et al. 2012). Here, ERBB2 is linked to breast carcinoma.